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Abstract
CHD7 is one of nine members of the chromodomain helicase DNA–binding domain family of ATP–dependent chromatin
remodeling enzymes found in mammalian cells. De novo mutation of CHD7 is a major cause of CHARGE syndrome, a genetic
condition characterized by multiple congenital anomalies. To gain insights to the function of CHD7, we used the technique
of chromatin immunoprecipitation followed by massively parallel DNA sequencing (ChIP–Seq) to map CHD7 sites in mouse
ES cells. We identified 10,483 sites on chromatin bound by CHD7 at high confidence. Most of the CHD7 sites show features
of gene enhancer elements. Specifically, CHD7 sites are predominantly located distal to transcription start sites, contain high
levels of H3K4 mono-methylation, found within open chromatin that is hypersensitive to DNase I digestion, and correlate
with ES cell-specific gene expression. Moreover, CHD7 co-localizes with P300, a known enhancer-binding protein and strong
predictor of enhancer activity. Correlations with 18 other factors mapped by ChIP–seq in mouse ES cells indicate that CHD7
also co-localizes with ES cell master regulators OCT4, SOX2, and NANOG. Correlations between CHD7 sites and global gene
expression profiles obtained from Chd7
+/+, Chd7
+/2, and Chd7
2/2 ES cells indicate that CHD7 functions at enhancers as a
transcriptional rheostat to modulate, or fine-tune the expression levels of ES–specific genes. CHD7 can modulate genes in
either the positive or negative direction, although negative regulation appears to be the more direct effect of CHD7
binding. These data indicate that enhancer-binding proteins can limit gene expression and are not necessarily co-activators.
Although ES cells are not likely to be affected in CHARGE syndrome, we propose that enhancer-mediated gene
dysregulation contributes to disease pathogenesis and that the critical CHD7 target genes may be subject to positive or
negative regulation.
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Introduction
CHD7(NM_017780) is a memberof the chromodomainhelicase
DNA binding domain family of ATP-dependent chromatin
remodeling enzymes. De novo mutation of CHD7 is a major cause
of CHARGE syndrome (OMIM 214800), a genetic condition
characterized by multiple congenital anomalies [1]. CHD7
mutations have also been reported in patients diagnosed with
diseases that have significant clinical overlap with CHARGE
syndrome, including Kallmann syndrome (OMIM 147950) [2–4],
Omenn-like syndrome (OMIM 603554) [5], and 22q11.2 deletion
syndromes [6]. Haploinsufficiency is the proposed mechanism of
disease pathogenesis, because most CHD7 mutations are nonsense
and frameshift predicted to be loss of function [7]. Studies in mice
support the haploinsufficiency model. Mice that are homozy-
gous for either nonsense or frameshift mutations in Chd7
(NM_001081417) die around embryonic day 10.5, while heterozy-
gous Chd7 mutants are viable and develop many of the features
observed in CHARGE syndrome [8]. These studies point to a
critical role for CHD7 in development, but that role is currently
unknown.
CHD7 is a nuclear protein that contains tandem N-terminal
chromodomains that mediate binding to methylated histones [9],
a central SNF2-like ATPase/helicase domain predicted to
mediate chromatin remodeling, a histone/DNA-binding SANT
domain, and two C-terminal BRK domains of unknown
function. Expression is widespread and high early in develop-
ment, with progressive restriction to CHARGE-relevant tissues
[8,10,11]. It is not known whether CHD7 binds directly to DNA,
but a role in transcription has been proposed based on homology
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[12]. Consistent with this notion, CHD7 is homologous to
Drosophila melanogaster Kismet (NM_078717), a trithorax family
member proposed to promote early transcriptional elongation
[13,14].
Structural determinants within the tandem chromodomains of
CHD7 are predicted to mediate docking of CHD7 to methylated
lysine 4 of histone H3 (H3K4me) [15]. Consistent with this
prediction, we recently showed through ChIP-chip studies that the
distribution of CHD7 correlates with all three methylated forms of
H3K4, with the majority of CHD7 sites overlapping mono- and
di-methylated H3K4 (H3K4me1/2) located at regions distal to
transcription start sites [9]. Interestingly, the distal CHD7 sites
show features of gene enhancer elements [16,17], i.e., in addition
to containing high levels of H3K4me1/2, distal CHD7 sites are
cell type specific and contained within ‘‘open’’ chromatin that is
hypersensitive to DNase I digestion (DNase HS). Moreover, three
out of six CHD7 binding sites functioned as enhancers when tested
in luciferase reporter assays. These data raise the possibility that
CHD7 is an enhancer-binding protein. However, because these
studies were limited to 1% of the genome, only a small number of
sites targeted by CHD7 were examined. Furthermore, the
relationship between CHD7 binding and cell-type specific patterns
of gene expression could not be adequately addressed. Whether or
not CHD7 directly functions to regulate transcription was not
assessed and remains unknown.
As a first step to investigate the function of CHD7, we used the
technique of chromatin immunoprecipitation followed by mas-
sively parallel DNA sequencing (ChIP-Seq) [18] to map CHD7
sites in mouse ES cells, representing the earliest precursor to all
tissues affected in CHARGE syndrome. By correlating the
location of CHD7 sites to histone modifications, gene expression,
numerous transcription factors and other publicly available
datasets, we show that CHD7 localizes predominantly to enhancer
elements. Correlations between CHD7 binding sites and global
gene expression profiles from Chd7 wildtype, heterozygous, and
null ES cells indicate that CHD7 functions to modulate, or fine-
tune, cell type-specific gene expression. This study establishes
CHD7 as a transcriptional regulator, highlights a novel mecha-
nism of enhancer-mediated regulation, and implies that the
multiple anomalies in CHARGE syndrome result from dysregu-
lated expression of tissue-specific genes.
Results
Characterization of genome-wide CHD7 occupancy using
ChIP–Seq analysis
We mapped the distribution of CHD7 on chromatin in mouse
ES cells using ChIP-Seq. We detected 27574, 10483, and 2916
CHD7 binding sites at low, middle, and high confidence
thresholds, respectively (Figure 1A). A representative example of
the ChIP-seq data is shown in Figure 1B. False discovery rates
(FDR) were calculated by comparing CHD7 sites identified by
ChIP-seq to those identified by ChIP-chip on 1% of the mouse
genome [9]. These ChIP experiments are biological replicates, and
therefore, FDRs may reflect some degree of biological variation or
platform-specific differences, rather than true false positives.
Nevertheless, at the lowest threshold, 44% of the CHD7 peaks
identified by ChIP-seq were also identified by ChIP-chip. These
percentages increase to 68% and 93% at the middle and high
thresholds, respectively.
Of 10483 CHD7 binding sites identified at the medium
confidence threshold, 16.4% (1723) are located within 1.5 kb of
a transcriptional start site (TSS). Of the remaining CHD7 sites,
46.0% (4819) are intergenic, 2.3% (239) are located within exons,
and 35.3% (3702) are intronic (Figure 1C). The distribution of
CHD7 is similar at the lower and higher thresholds, although
fewer CHD7 sites are found at TSSs at high threshold (7.8%
versus 16.4%). This discrepancy is due to differences in CHD7
signal intensity, i.e., CHD7 signals at TSSs are generally lower
than at distal regions (Figure 2B and 2C), causing signals at TSSs
to ‘‘drop out’’ when thresholds are increased. The rest of the
analyses were performed using the 10483 CHD7 sites identified at
the medium threshold.
CHD7 binding sites have similar characteristics to gene
enhancer elements
Based on previous studies suggesting that CHD7 binds
enhancers [9], we implemented ChIP-seq on mouse ES cells to
map the genome-wide distribution of P300 (NM_177821), a
known enhancer-binding protein [19]. In addition, we generated
a genome-wide map of open chromatin in mouse ES cells using
the technique of DNase-seq [20]. The location of the P300 sites
and the open regions of chromatin were compared to the
distribution of CHD7, along with the locations of the following
seven different histone modifications previously mapped by
ChIP-seq: H3K4me1, H3K4me2, H3K4me3, H3K9me3,
H3K27me3, H3K36me3, and H4K20me3 [21,22]. The strategy
for comparing these datasets is outlined in Figure 2A and the
results are plotted as a heatmap in Figure 2B. The heatmap
reveals several distinct clusters defined by the presence or absence
of specific histone marks and/or factors. Sites containing the most
robust CHD7 signals cluster in the upper third of the heatmap.
These sites show features of enhancer elements, including high
levels of H3K4me1, H3K4me2, and P300. The CHD7 sites are
also contained within open regions of chromatin that are
hypersensitive to DNase I digestion (DNase HS). In comparison,
the cluster in the lower portion of the heatmap, which has lower
levels of CHD7, display the characteristic features of promoters.
Specifically, these sites have high levels of H3K4me3 and
H3K4me2, and are DNase HS. As previously described, these
promoter regions also contain low levels of H3K4me1 as a
distinctive bimodal peak centered over the TSS [23]. Also as
expected for promoters in this cluster, the level of H3K36me3 is
Author Summary
The gene encoding chromodomain helicase DNA–binding
protein 7 (CHD7) is required for normal mammalian
development. In humans, genetic mutations in CHD7 lead
to CHARGE syndrome, a disorder characterized by multiple
birth defects. In previous studies, CHD7 was shown to
localize to the cell nucleus and bind to specific sites on
chromatin. However, the genome-wide distribution of
CHD7 on chromatin and its function are not known. Here,
we identified 10,483 sites on chromatin bound by CHD7 in
mouse embryonic stem cells. Many of these sites are gene
enhancer elements suspected to be involved in turning on
genes. We show CHD7 functions at these loci to fine-tune
the levels of genes that are specifically expressed in mouse
ES cells. This modulation is mediated through several
proteins that bind together with CHD7 at enhancer
elements and can occur in either direction. These findings
suggest CHARGE syndrome is the result of key genes that
are improperly expressed during development. These key
genes are currently unknown but are likely to be tissue-
specific and may be upregulated or downregulated in
response to CHD7 mutation.
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transcriptional elongation [24]. CHD7 is absent from clusters
containing histone marks generally associated with gene repres-
sion, including H3K9me3, H3K27me3, and H4K20me3 [25].
Overall, these results are consistent with CHD7 binding to a
subset of enhancer elements and, to a lesser extent, promoter
regions. This is also apparent when the regions identified as
enhancers and promoters are aggregated and plotted (Figure 2C).
The difference between CHD7 signals at enhancers and pro-
moters could reflect recruitment of CHD7 to enhancers and
subsequent transient association with promoters via looping.
Further studies are required to test this looping model.
CHD7 co-localizes with P300, OCT4, SOX2, and NANOG at
active gene enhancer elements
The locations of the following 13 transcription factors were
recently mapped by ChIP-Seq: NANOG (NM_028016), OCT4 (also
called POU5F1, NM_013633), STAT3 (NM_213659), SMAD1
(NM_008539), SOX2 (NM_011443), ZFX (NM_011768), c-MYC
Figure 1. CHD7 ChIP–Seq analysis in mouse ES cells. (A) Total number of ChIP-Seq peaks representing genome-wide CHD7 binding sites at
three thresholds and corresponding false-discovery rates (FDR). (B) Integrated Genome Browser view of mapped sequence tags from CHD7 ChIP-
Seq analyses with low, medium, and high thresholds shown as horizontal lines. (top panel) Data from mouse chromosome 19. (bottom panel)
Zoomed view of individual CHD7 ChIP-seq peaks. (C) Pie chart depicting the location of CHD7 binding sites relative to known genes (mm8
assembly).
doi:10.1371/journal.pgen.1001023.g001
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PLoS Genetics | www.plosgenetics.org 3 July 2010 | Volume 6 | Issue 7 | e1001023Figure 2. CHD7 localizes to enhancers and promoters. (A) Strategy for characterizing CHD7 binding sites (see Materials and Methods). (B)
CHD7 binds to sites containing the characteristics of gene promoters and enhancers. The scale corresponds to relative signal intensities; dark blue
reflecting high signal intensity, white-grey reflecting weak signal intensity. Light blue corresponds to genomic regions containing highly repetitive
sequence. (C) Aggregate plot of signals corresponding to the regions indicated by the brackets in B.
doi:10.1371/journal.pgen.1001023.g002
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ESRRB (NM_011934), TCFCP2L1 (NM_023755), E2F1
(NM_007891), and CTCF (NM_181322) [26]. Interestingly, iterative
pairwise comparisons between all 13 datasets indicated that specific
sites in the genome are extensively co-occupied by multiple
transcription factors. Genomic segments bound by 4 or more factors
were termed multiple transcription factor loci, or MTLs. MTLs are
further distinguishable by distinct combinations of proteins. For
example, NANOG, OCT4, SOX2, SMAD1, and STAT3 tend to
co-localize to one set of MTLs, while c-MYC, n-MYC, ZFX, and
E2F1 co-occupy different MTLs. Interestingly, 25 out of 25 loci co-
occupied by NANOG, OCT4, SOX2, SMAD1, and STAT3
functioned as enhancers when placed downstream of a luciferase
reporter. By comparison, 0/8 constructs containing genomic
fragments co-bound by proteins in the Myc cluster activated the
luciferase reporter. These data, along with correlations to corre-
sponding gene expression data, indicate that ES cell-specific gene
expression is mediated by combinatorial binding of OCT4, SOX2,
NANOG, SMAD1, and STAT3 to enhancer elements.
We tested whether CHD7 co-localizes to enhancer elements
with any of the previously mapped factors in ES cells. To do this,
pairwise comparisons were made between the binding sites of
CHD7, P300, the 13 factors listed above, and the following four
factors for which public data is available: SUZ12 (NM_199196),
RING1B (NM_011277), EZH2 (NM_007971), and BRG1
(NM_011417) [27,28]. Odds ratios representing the correlation
between binding sites for each pair of factors were calculated,
hierarchically clustered, and plotted in heatmap (Figure 3A). Using
this strategy, we identified 3 clusters of proteins that co-localize to
specific loci within the ES cell genome. The smallest cluster is
defined by proteins that comprise the Polycomb-repressive
complexes, and includes SUZ12, RING1B and EZH2. The next
smallest cluster is identical to that mentioned above, and contains
c-MYC, n-MYC, E2F1, and ZFX. The largest cluster is defined by
the presence of both CHD7 and P300 and the five factors
previously shown to colocalize to functional enhancers: OCT4,
SOX2, NANOG, SMAD1, and STAT3. In contrast, the insulator
binding protein CTCF did not show strong association with any of
the factors [29]. We used ChIP-PCR assays to validate the
presence of CHD7 at six loci that showed co-occupancy of MTLs
containing OCT4. As a control for specificity, CHD7 binding at
these sites was assayed in ES cells harboring a homozygous
nonsense mutation in the Chd7 gene (W973X) and shown to be
negative (Figure S1).
Five CHD7-OCT4 MTLs were tested for enhancer activity
using a luciferase reporter assay. All five constructs showed robust
activity in ES cells and this activity was ES cell specific (Figure 3B).
These constructs were also capable of activating luciferase in
CHD7 null mouse ES cells, suggesting that CHD7 is dispensable
for enhancer activity at these MTLs. Collectively, these findings
indicate that CHD7 is associated with core components of the
transcriptional circuitry of ES cells that functions to mediate ES
cell-specific gene expression via an enhancer-binding mechanism.
Although CHD7 appears to be dispensable for enhancer activity,
we cannot rule out the possibility that CHD7 sites outside of the
five tested are dependent on CHD7, or if genes that are regulated
by multiple, cooperating enhancers are influenced by loss of
CHD7. We also cannot exclude the possibility that enhancer-
activity is dependent on CHD7 at later stages in development, in
cell types that are more relevant than ES cells to the phenotype of
CHARGE syndrome.
We next tested whether binding of CHD7 is dependent on
OCT4 binding to MTLs. CHD7 ChIP was performed at five
CHD7/OCT4-MTLs in ES cells transfected with Oct4 shRNA.
The data show that CHD7 binding is diminished upon
knockdown of OCT4 (Figure 3C), indicating that OCT4 is
required for the binding of CHD7. To test if OCT4 binding is
dependent on CHD7, OCT4 ChIP was performed at the same
five MTLs in wildtype and Chd7 null ES cells. The results show
that CHD7 is not required for binding of OCT4 (Figure 3D).
These results not only validate combinatorial binding of these
specific factors, but also are consistent with published data
indicating that OCT4 is the key factor required for stabilizing
complex formation at functional enhancer elements [26].
CHD7 co-immunoprecipitates with P300
Given the strong evidence that P300 binds to functional
enhancers [19], we further delineated the relationship between
CHD7 and P300 binding by comparing 1000 randomly selected
CHD7 and P300 binding sites using the approach outlined in
Figure 2A. A heatmap can reveal signals that are below threshold
but above background, and therefore this plot is far more
informative than a Venn diagram. The heatmap indicates that
the most robust CHD7 binding sites are also shared by P300,
although a number of robust P300 sites altogether lack CHD7.
Weaker, but significant CHD7 binding sites harbor little to no
P300 binding (Figure 4A). A direct interaction between CHD7
and P300 was then tested by co-immunoprecipitation. P300 was
successfully co-immunoprecipitated with antibodies to CHD7,
although reciprocal co-IP of CHD7 with P300 antibodies was not
observed (Figure S1).
Delineation of enhancer activity at CHD7 sites bound and
not bound by P300
We selected 67 CHD7 binding sites and cloned them
downstream of a luciferase reporter driven by the Oct4 minimal
promoter. 36 of the 67 sites were cobound by P300 and CHD7,
and the remaining 31 showed minimal or undetectable P300
binding. Upon transfection into wildtype ES cells, 23/36 (63.8%)
of the sites bound by both P300 and CHD7 showed greater than
a 3-fold increase in luciferase activity over negative controls
(Figure 4B). Using this same threshold, 7/31 (22.6%) sites bound
by CHD7 alone showed enhancer activity, and the level of
activity was less robust than that determined for sites bound by
both P300 and CHD7. Overall the data suggest that highly active
enhancers contain P300 and are consistent with previous studies
indicating that P300 accurately predicts enhancer function. The
data also indicate that sites bound by CHD7 and not P300
represent a subset of functional enhancers that generally show
modest activity.
ES cell-specific gene expression correlates with CHD7
occupancy at gene enhancers
Given that enhancers function to mediate tissue-specific gene
expression, we hypothesized that CHD7 sites identified by ChIP-
seq would positively correlate with ES cell-specific gene expres-
sion. To test this hypothesis, we utilized genome-wide expression
data from multiple cell types to group genes that are: (1)
specifically expressed in ES cells, (2) specifically repressed in ES
cells, and (3) non-specific to ES cells. These gene sets were
generated by comparing global gene expression levels between
mouse ES cells, neural precursors (NP) derived from ES cells, and
embryonic fibroblasts (MEF) and computing a tissue-specificity
score for each gene using Shannon-entropy [30]. The distribution
of expression of genes within each set is shown in Figure 5A. We
then calculated and plotted the average number of CHD7 binding
sites within 200 kb of the TSS of each gene in each set (Figure 5B
CHD7 Modulates ES-Specific Expression
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expression have far more CHD7 binding sites than genes that are
specifically repressed in ES cells or not specific to ES cells. Similar
results are obtained when genes are ranked by the specificity of
their expression in ES cells and plotted against the number of
CHD7 binding sites (Figure 5D). Collectively, the results show a
very strong correlation between CHD7 binding and ES-specific
gene expression.
Figure 3. CHD7 co-localizes with core ES cell factors at functional enhancer elements. (A) Co-localization of transcription factors. Colors in
the heat map correspond to the colocalization frequency of each pair of factors; yellow reflecting high correlation, and blue reflecting little or no
correlation. The three clusters referred to in the text are highlighted in the red boxes. (B) Genomic fragments from CHD7/OCT4 MTLs show CHD7-
independent enhancer activity. Sites from the CHD7/OCT4 MTLs were cloned into a luciferase reporter vector and assayed for enhancer activity in
both in wild type (+/+) and Chd7 null (2/2) ES cells. The western blot (upper right) shows the levels of CHD7 protein in wild type and Chd7 null ES
cells. MENIN is a nuclear protein that serves as a loading control [49]. No enhancer activity was observed upon transfection of constructs into mouse
embryonic fibroblasts (not shown). EV = empty vector control. (C) CHD7 occupancy is dependent on OCT4. CHD7 ChIP at five CHD7/OCT4-MTLs is
shown in ES cells transfected with either Oct4 shRNA or a control RNAi construct (EV control). NT = non-target control region. The levels of OCT4 in
control and Oct4-shRNA transfected cells are shown in the western blot (upper right). (D) OCT4 occupancy is not dependent on CHD7. OCT4 ChIP at
the same five MTLs as in panel C is shown in wild type and CHD7 null cells.
doi:10.1371/journal.pgen.1001023.g003
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reprogramming are not dependent on CHD7 function
The data above indicate that CHD7 co-localizes with
components of the core transcriptional circuitry in ES cells,
including OCT4, SOX2, and NANOG. Moreover, CHD7 binds
to loci encoding proteins proposed to mediate ES cell self-renewal
and pluripotency, including OCT4, SOX2, and NANOG, as well
as DPPA2 (NM_028615), DPPA4 (NM_028610), MYC, and
SALL4 (NM_201396) (Figure S2) [31]. However, Chd7 null mice
die in mid-gestation, far beyond the ES cell stage. We therefore
would not necessarily expect the loss of CHD7 to overtly affect the
functions of ES cells. Nevertheless, we tested whether the processes
of ES cell self-renewal, pluripotency and/or somatic reprogram-
ming are affected by the loss of CHD7.
Chd7 null ES cells do not spontaneously differentiate in culture or
exhibit any detectible growth defects (data not shown). Moreover, the
levels of Oct4, Sox2,a n dNanog are similar between wildtype and Chd7
null ES cells (Figure S3). These results indicate that the processes of ES
cell self-renewal are not overtly affected by absence of CHD7. To test
if absence of CHD7 affects pluripotency, wildtype and Chd7 null ES
cells were differentiated into embryoid bodies (EBs) and multiple gene
markers for endoderm, ectoderm, and mesoderm formation were
quantified by qRT-PCR (see Materials and Methods). In addition, the
levels of Oct4, Sox2,a n dNanog were quantified to determine if CHD7
influences the rate of differentiation. Chd7 levels increase at day 4 of
EB formation and remain high throughout EB formation (Figure S3).
All other genes tested responded as expected over the course of EB
formation, and no significant expression differences were observed
between wildtype and Chd7 null cells (Figure S3 and data not shown).
Lastly, we tested if absence of CHD7 affects somatic cell
reprogramming by generating inter-species heterokaryons with Chd7
null mouse ES cells [32]. Similar to wildtype ES cells, Chd7 null ES
cells fused to human B cells activated pluripotency genes including
hOct4 (NM_002701), hNanog (NM_024865), hCripto (NM_003212),
and hDnmt3b (NM_006892) (Figure S5). Collectively, the results
indicate that CHD7, despite being associated with the core
transcriptional circuitry in ES cells, is not essential for the
processes of ES cell self renewal, pluripotency, or somatic cell
reprogramming.
CHD7 functions as a repressive modulator of ES cell–
specific gene expression
To determine the role of CHD7 at enhancers, we obtained
global gene expression profiles from Chd7 wildtype, heterozygous,
and null ES cells. Using methodology similar to that used to
generate ES-specific gene sets, we classified genes as decreased,
increased or not differentially expressed between wildtype and
Chd7 null ES cells (Figure 6A). Interestingly, genes that are
differentially expressed reside within the upper range of the
overall distribution of ES cell gene expression, indicating that
genes influenced by loss of CHD7 are generally expressed at
relatively high levels (Figure 6A, compare red and green boxes to
the white boxes). Similar to above, we then counted and plotted
the average number of CHD7 sites within 200 kb of the TSS of
each gene within each set. The results indicate that significantly
more CHD7 sites are located near genes that increase upon loss
of CHD7 than genes that decrease or are not differentially
expressed (Figure 6B and 6C; compare green plot to red and
black plots). Moreover, genes that increase upon loss of CHD7
are more ES cell specific than the genes in the other two
Figure 4. CHD7 sites bound and not bound by P300 can activate transcription. (A) Comparison of 1000 randomly selected P300 sites to
1000 randomly selected CHD7 sites. (B) Enhancer assay. OCT4 sites correspond to MTLs that were previously shown to activate the luciferase reporter
gene and serve as positive controls. MYC sites correspond to Myc MTLs that fail to activate the luciferase reporter gene and serve as negative
controls. -, untransfected.
doi:10.1371/journal.pgen.1001023.g004
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CHD7 occupancy and reduced gene expression suggests that
CHD7 functions to limit the expression of a subset of ES-specific
genes. Moreover, because the loss of Chd7 results in relatively
modest expression changes of genes that are already highly
expressed, the repressive action of CHD7 is modulatory in
nature. Similar results are observed in comparisons between
wildtype and Chd7 heterozygous cells, as well as comparisons
between heterozygous and null ES cells (Figure S4). Thus, the
association between CHD7 binding and repressive modulation of
ES cell-specific expression is unlikely to be due to ES clone-
specific effects, and additionally indicates that CHD7-mediated
regulation is dosage dependent.
CHD7 sites near differentially repressed genes show
similar characteristics to those located elsewhere in the
genome
We selected CHD7 sites located within 200 kb of the
differentially repressed genes in wildtype ES cells and examined
Figure 5. CHD7 binding correlates with ES cell specific expression patterns. (A) Distribution of expression of genes within each set. Mouse
genes were classified as ES-specific expressed (red), ES-specific repressed (green), and non-specific (gray) based on the specificity of their expression
in ES cells, as compared to neural precursor (NP) and mouse embryonic fibroblasts (MEF). (B) CHD7 localization relative to ES-specific expressed genes
(red), non-specific expressed (black), and ES-specific repressed (green). The P-value reflects significance of CHD7 enrichment of ES-specific expressed
genes compared to non-specifically expressed genes, as determined by a Wilcoxon signed-rank test. Average peak count refers to the average
number of CHD7 binding sites at various distances within 200-kb of the TSS of the genes in each set. The table below the plot shows the average
number of binding sites per gene within smaller intervals defined by the width of the grey triangles. (C) Average number of CHD7 binding sites per
gene in each gene set. CHD7 sites within 20 kb of a TSS are distinguished from sites located between 20 and 200 kb. (D) Comparison of CHD7
enrichment and ES cell-specific gene expression.
doi:10.1371/journal.pgen.1001023.g005
CHD7 Modulates ES-Specific Expression
PLoS Genetics | www.plosgenetics.org 8 July 2010 | Volume 6 | Issue 7 | e1001023them in detail. Similar to sites located across the entire
genome, CHD7 sites at repressed genes are frequently co-
occupied by P300, OCT4, SOX2, NANOG, SMAD1, and
STAT3 (Figure 7A). Furthermore, although we do detect a
slightly higher proportion of CHD7 sites at promoters containing
H3K4me3 (,25% versus ,16%), sites near the genes subject to
CHD7-directed negative modulation have similar characteristics
to those found elsewhere, i.e., most contain high levels of P300
and H3K4me1/2, relatively low levels of H3K4me3, and are
contained within open chromatin that is hypersensitive to DNase
I digestion (Figure 7B). These findings support the notion that the
repressive modulatory action of CHD7 is indeed related to its
binding to enhancer elements, rather than a different type of
functional element.
Figure 6. CHD7 modulates ES cell specific expression. (A) Distribution of gene expression in wild type (+) and CHD7 null (2) ES cells. Genes
were defined as decreasing (red, n=800), increasing (green, n=1200), or not changing (gray, n=1000) upon loss of CHD7. The white boxplots
represent the genome-wide distribution of gene expression in either wild type or Chd7 null ES cells. (B) CHD7 is significantly enriched near genes that
increase in expression upon loss of CHD7. The P-value reflects significance of CHD7 enrichment of differentially increased genes (green) compared to
non-differentially expressed genes (black). Comparisons between differentially decreased genes (red) and non-differentially expressed genes were
insignificant. Similar results are obtained when CHD7 sites are correlated to smaller gene sets containing the top 100, 200, or 400 differentially
expressed genes (data available upon request). (C) Average number of CHD7 binding sites per gene for each gene set. CHD7 sites located near TSSs
are distinguished from those located distal to TSSs. (D) To determine whether differentially expressed genes are ES cell specific, genes in each of the3
classes above were scored according to the specificity of their expression in ES cells, as compared to NP and MEFs. The distribution of the ES-
specificity scores for genes in each of the 3 sets was then superimposed on the plot from Figure 4D. Note that ES cell specificity scores for genes that
increase upon loss of CHD7 (green) are located on the left side of the plot, compared to genes that either decrease (red) or are not differentially
expressed (gray). Arrows correspond to median specificity scores for each gene set.
doi:10.1371/journal.pgen.1001023.g006
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The adoption of genome-wide approaches for mapping
transcription factors and histone-modifications by the ENCODE
consortium and other groups has helped to rapidly identify the
genomic locations of functional elements and their characteristics.
As demonstrated here for CHD7, these efforts are facilitating
functional characterization of chromatin-associated proteins,
because once generated, multiple datasets can be compared to
infer a protein’s function. However, as more and more factors are
mapped, it is becoming increasingly apparent that multiple
proteins often co-occupy a given functional element, and the
functional significance of this is unclear. For instance, our studies
and others indicate that at least 12 factors bind to the distal
enhancer of Oct4 in ES cells [26]. Some factors are clearly essential
for maintaining normal cell function. For example, reduction of
OCT4 [33], SOX2 [34], or SALL4 [35] results in rapid
differentiation of ES cells, indicating that these proteins play
critical roles in the ES cell circuitry to maintain self-renewal and
pluripotency. Our studies indicate that CHD7, although not a
critical component of the ES cell circuitry, functions at enhancers
to modulate the expression levels of ES-specific genes. The
modulation can occur in either the positive or negative direction,
however negative-regulation appears to be the more direct effect of
CHD7 binding. This modulatory role suggests that regulation of
tissue-specific gene expression involves the coordinated combina-
torial binding of not only potent regulators that switch genes on
and off, but also factors that mediate fine-tuning. A model for
CHD7 function is shown in Figure 8.
The mechanism by which CHD7 modulates transcription in ES
cells is currently unknown and will be the subject of future
investigation. However, it is well established that chromatin-
remodeling proteins exist in large multi-subunit complexes, and
the composition of proteins within these complexes determines
how these proteins control transcriptional programs and establish
cellular identity [36–38]. As this manuscript was under review,
CHD7 was found to physically associate with PBAF (polybromo-
and BRG1-associated factor containing complex) [39]. Through
our colocalization analyses, we detected overlap between sites
occupied by CHD7 and BRG1 (Figure 3A), although the extent of
overlap was not as significant as that for other factors.
Interestingly, BRG1 was shown through ChIP-seq studies to
colocalize to chromatin with OCT4, SOX2, and NANOG in ES
cells, and to both positively and negatively regulate transcription
Figure 7. CHD7 binding sites near CHD7-regulated genes show the features of enhancer elements. (A) Colocalization of proteins near
genes negatively regulated by CHD7. Similarly to CHD7 sites located elsewhere in the genome, CHD7 colocalizes with P300, OCT4, SOX2, NANOG,
SMAD1 and STAT3 at regions associated with CHD7-mediated regulation. (B) CHD7 sites associated with negative modulation (n=3118) were
correlated to histone modifications, P300 binding sites, and open chromatin, as in Figure 2.
doi:10.1371/journal.pgen.1001023.g007
Figure 8. Model for CHD7-mediated transcriptional modulation in ES cells. CHD7, via its tandem chromodomains, binds to functional gene
enhancers marked with mono- and di-methylated K4 of histone H3. In ES cells a subset of the CHD7 sites are cobound by P300, OCT4, SOX2, and
NANOG. Collectively, these proteins coactivate gene expression through enhancer-promoter interactions. A subset of CHD7 sites that are not bound
by P300, OCT4, SOX2, and NANOG can also enhance transcription, although the identity of the CHD7-associated factors at these sites is not known
(not shown). Reduction of CHD7 levels results in increased transcription of a subset of ES cell-specific genes that are already expressed at reasonably
high levels, suggesting an antagonistic role for CHD7 at enhancers. We hypothesize that CHD7 functions similarly at later stages in development,
which would imply that dysregulated expression of tissue-specific genes contributes to the pathogenesis of CHARGE syndrome.
doi:10.1371/journal.pgen.1001023.g008
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mechanism of CHD7 as both a positive and negative regulator is
related to its interactions with BRG1-containing complexes.
However, we also found that a substantial fraction of CHD7 sites
do not contain BRG1, and we therefore cannot rule out the
possibility that CHD7 cooperates with other, currently unidenti-
fied proteins to regulate transcription. CHD7 co-localization
analyses with factors in addition to the 18 we tested, as their
binding profiles become available, could help reveal these
interactions.
How might haploinsufficiency of CHD7 give rise to CHARGE
syndrome? We hypothesize that dysregulated tissue-specific gene
expression is the underlying cause. This hypothesis is supported
not only by the evidence presented here, suggesting a role for
CHD7 as a modulator of transcription in ES cells, but also by
previous studies suggesting that CHD7 binds to enhancer elements
in differentiated cell types [9]. As in ES cells, the effect of reduced
CHD7 levels on transcription may be modest during development.
Modest effects could translate into dramatic effects that perturb
development, particularly if CHD7 directly regulates a critical
transcription factor. However, the possibility that haploinsuffi-
ciency of CHD7 induces large transcriptional effects at time points
beyond the ES cell stage still needs to be tested. Given that the
affected tissues in CHARGE syndrome are derived from multiple
germ layers, we also cannot rule out the possibility that the subtle
expression changes occurring at the ES cell stage could themselves
contribute to the phenotype, although this scenario is unlikely
given that Chd7-null ES cells are capable of differentiating into all
three germ layers. Future studies aimed at investigating gene
expression patterns in relevant tissues from CHD7 mutant mice
could help shed light on these and other possibilities. In that
regard, defects in neural crest cell migration were recently
proposed to underlie the anomalies in CHARGE syndrome
[39]. Thus, neural crest cells might serve as excellent resource for
identification of critical CHD7 target genes. The data presented
here suggest that the critical target genes are likely to be neural
crest-specific, and may be either upregulated or downregulated
inappropriately when CHD7 is haploinsufficient.
Materials and Methods
Ethics statement
Studies involving mice are approved by the CWRU Animal
Care and Use Committee.
ChIP–Seq and DNase–Seq
R1 ES cells were cultured under feeder-free conditions as
previously described [9]. Chromatin preparation, ChIP, DNA
purification, and library preparation for Illumina sequencing were
performed as described [40]. ChIP was performed using
commercially available antibodies to CHD7 (Abcam, ab31824)
and P300 (Santa Cruz, sc-585). Sequencing was done on an
Illumina GAII instrument according to the manufacturer’s
protocol. For CHD7 and P300, 9,154,400 and 19,480,925 unique
reads were obtained, respectively. The Eland software (Illumina)
was used to align reads with up to two mismatches against the
mm8 reference genome. Regions significantly enriched for CHD7
or P300 binding were identified using F-seq, a feature density
estimator for high-throughput sequence tags [41]. Genomic
regions found to have an unexpectedly high percentage of reads
aligning to the sample positions, indicating PCR artifacts, were
eliminated from the analysis. Also excluded from the analysis were
CHD7 peaks in which the midpoint overlapped a repetitive
region. DNase-Seq was performed as previously described [42].
Sequences obtained from 8 lanes of sequencing on an Illumina
GAII instrument (38,342,306 reads) were aligned to the mouse
genome (mm8) using MAQ [43], and peaks corresponding to
DNase HS sites were determined using F-seq. All data, including
the list of CHD7, P300, and DNase HS peaks will be deposited in
GEO upon publication.
Cluster analysis
For cluster analyses in Figure 2, 100 high-confidence peaks on
mouse chromosome 19 were randomly selected from DNase-seq
data, CHD7 and P300 ChIP-seq data, and the following seven
publically available ChIP-seq datasets: H3K4me3, H3K9me3,
H3K27me3, H3K36me3, H4K20me3 (GSE12241); H3K4me1,
H3K4me2 (GSE11172) [21,22]. A 10 kb window centered on the
midpoint of each peak was then generated. The 10 kb region was
divided into 20 bins of 500 bp, and an enrichment value
corresponding to the median number of sequence reads in each
bin was calculated. To allow for comparisons between factors with
different normal distributions, data were standardized using a Z-
score transformation. Normalized data from each ChIP-seq/
DNase-seq dataset were then aligned in parallel columns to create
a 1000 row610 column matrix. The data in the rows were then K-
means clustered (Euclidian distance, 1000 runs, 5 clusters) in Gene
Cluster 3.0 [44]. Clusters were visualized with Java Treeview [45].
Generation of wild-type and Chd7 mutant ES cell lines
Timed matings between male and female heterozygous Whirligig
mice [8], strain C3HeB/FeJ, were set up. Whirligig mice harbor a
G2918A transition in exon 11 of the Chd7 gene, resulting in a
W973X nonsense mutation. From the inner cell mass of fourteen
blastocysts harvested from pregnant females, one wild type, three
Chd7 heterozygous and two Chd7 homozygous lines ES cells were
generated as previously described [46].
Differentiation of ES cells to embryoid bodies
One Chd7 wildtype and two Chd7
2/2 ES cell lines were
differentiated into embryoid bodies according to standard
protocols. Cells were harvested at days 0, 2, 4, 7, and 10 during
EB formation. The following genes were assayed in triplicate by
standard qRT-PCR using SyBr green detection: Chd7, Gapdh, beta-
actin, Oct4, Sox2, and Nanog. The following germ layer-expressed
genes were assayed: Sox1 and Fgf5 (ectoderm); Gsc and T
(mesoderm); Afp, Sox17, and Gata6 (endoderm); Sox7 and Hhex
(visceral endoderm). Primer sequences are available upon request.
Microarray analyses
Expression datasets for mouse ES, neural precursor (NP), and
embryonic fibroblast cells were downloaded from Gene Expres-
sion Omnibus (Accession number: GSE8024) [22]. Raw data were
RMA normalized using the R Affy package [47] available in
Bioconductor [48]. Chd7 wildtype, heterozygous, and homozygous
ES cells derived from preimplantation embryos were grown on
feeder cells and total RNA was isolated using Trizol. The ratio of
ES to feeder cells was estimated at 5:1. RNA was labeled and
hybridized to Illumina Mouse Ref-8 v2 Expression BeadChIP
microarrays according to the manufacturer’s instructions. Raw
data were background subtracted and quantile normalized using
Illumina Bead Studio software.
Generation of gene sets
Shannon entropy was used to rank genes by the specificity of
their expression in ES cells compared to NP cells and MEFs [30].
To generate a list of ES-specific expressed genes, genes were first
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ES cell specific. The entire gene list was then divided into blocks of
400 genes. Expression levels of the top 400 genes were then
compared between ES, NP and MEFs using a T-test. This process
was repeated for subsequent gene blocks until a significant
difference in expression (P,0.05) was no longer achieved. This
occurred between blocks 11 and 12, encompassing 4500 genes that
we consolidated into one list of ES-specific expressed genes. The
list of ES-specific repressed genes was generated in the same
manner, except that genes were first sorted by their Shannon
entropy scores from least to most ES cell-specific. This process
yielded 4469 ES-specific repressed genes. 4000 genes in the middle
of the list and not significantly differentially expressed among ES
cells, NP cells and MEFs were selected for the set of non-
differentially expressed genes. A similar approach was used to
define genes that were decreased, increased, and not differentially
expressed between Chd7 wildtype, heterozygous, and null ES cells.
A total of 800 genes in wildtype ES cells were significantly
decreased in expression in Chd7 null ES cells (p,0.00003). 1200
genes in wildtype ES cells were significantly increased in
expression in Chd7 null ES cells (p,0.003). 1000 genes that were
not significantly different between wildtype and null cells were
used for the list of non-differentially expressed genes (p.0.05).
The identity of the genes within each set, as well as their respective
fold changes and corresponding number of CHD7 sites are listed
in Table S1, S2, and S3.
Generation of colocalization maps
The following ChIP-seq datasets were downloaded from GEO:
OCT4, SOX2, NANOG, SMAD1, KLF4, ESRRB, CTCF, n-
MYC, c-MYC, STAT3, E2F1, TCFCP2L1, ZFX (GSE11431)
[26]; BRG1 (GSE14344) [27]; SUZ12, EZH2, RING1B
(GSE13084) [28]. The binding sites for these factors in addition
to CHD7 and P300 (19 in total) were assembled into one list. Sites
located within 200 bp of eachother were consolidated. The final list
contained 121,362 unique binding sites. Each binding site was then
examined for the presence of each of the 19 factors. An odds ratio
from a Fishers Exact test, representing the correlation between
bindingsites for each pair of factors,was then calculated. Oddratios
were organized in a 19619 matrix and hierarchically clustered
using Cluster 3.0 and data were visualized in Java TreeView.
Luciferase assays
Constructs containing CHD7/OCT4 MTLs located downstream
of a Pou5f1 minimal promoter driving luciferase were kindly provided
from Huck-Hui Ng (Genome Institute of Singapore). The coordinates
for the CHD7/OCT4 MTLs are as follows (mm8): chr7:11914503-
11914844, chr5:103964736-103965061, chr8:75263314-75263637,
chr8:50250752-50251069, chr16:84651775-84652095. The coordi-
nates corresponding to the 67 CHD7 sites tested in Figure 4 are listed
in Table S4 in the same order as shown in Figure 4. Constructs
containing MTLs were transfected in triplicate into Chd7 wildtype and
null ES cells using Lipofectamine 2000 (Invitrogen). Constructs
containing the 67 CHD7 sites were transfected into R1 ES cells. In all
instances a renilla luciferase plasmid (pRL-SV40 from Promega) was
cotransfected as an internal control. Media was replaced after 24hrs
with fresh media and cells were harvested after a total of 48hrs.
Reported luciferase expression levels are relative to internal renilla
control.
OCT4 RNAi
Wild type ES cells were transfected with an Oct4 shRNA
construct commercially available from (Oligoengine) as previous-
ly described (Chen et al 2008). Puromycin selection was
introduced 1 day after transfection, and the cells were crosslinked
and harvested for ChIP 48 hours after transfection. pSuper-puro
empty vector was used as negative control. OCT4 knockdown did
not affect the level of CHD7 protein, as determined by western
blot.
ChIP–PCR
ChIPreactionswereperformed aspreviouslydescribed[9].OCT4
ChIP was performed using sc-8628 antibody from Santa Cruz. The
coordinates of the five target regions assayed in Figure 3C and 3D are
as follows (mm8): chr4:57785004-57785106, chr1:77337105-
77337241, chr4:55498595-55498713, chr8:91893769-91893867,
chr8:75263369-75263582. The coordinates for the control, non-
target regions are as follows (mm8): chr5:115216446-115216688,
chr11:100842467-100842708, chr14:88596378-88596635.
Supporting Information
Figure S1 (A) CHD7 ChIP in wild type and Chd7 null ES cells.
(B) CoIP experiments.
Found at: doi:10.1371/journal.pgen.1001023.s001 (1.55 MB EPS)
Figure S2 CHD7 ChIP-seq signals at genes that mediate ES cell
self-renewal and pluripotency.
Found at: doi:10.1371/journal.pgen.1001023.s002 (1.23 MB EPS)
Figure S3 Chd7 null ES cells differentiate normally into
embryoid bodies. qRT-PCR of indicated genes in one wild type
and two Chd7 null ES cells before, during, and after differentiation
into embryoid bodies. Other genes quantified include Sox1, Fgf5,
Gsc, T (brachyury), Afp, Sox17, Gata6, Sox7, and Hhex (not shown).
The expression of these genes in two Chd7
2/2 ES cell lines was
not significantly different from that in wildtype ES cells.
Found at: doi:10.1371/journal.pgen.1001023.s003 (1.28 MB EPS)
Figure S4 CHD7 transcriptional regulation is dosage-depen-
dent. (a) (left) Distance versus the average number of CHD7
binding sites per gene for genes that decrease (red), increase
(green), or remain the same (black) in Chd7 heterozygotes as
compared to wild type cells. Similar to the comparisons between
wild type and null cells, CHD7 sites correlate best with genes that
increase in expression upon reduction of CHD7 levels. The
distribution of expression of genes in each gene set are shown on
the right (b) Same analysis as in (a), but comparing Chd7
heterozygous cells to Chd7 homozygous null ES cells.
Found at: doi:10.1371/journal.pgen.1001023.s004 (0.96 MB EPS)
Figure S5 Absence of CHD7 does not affect reprogramming.
Wild type and Chd7 null ES cells were fused with human B
lymphocytes to create heterokaryons. Expression of the indicated
genes was measured by qRT-PCR before cell fusion (hB),
immediately after cell fusion (d0), and each day following for 3
days. hHprt served as a control gene marker. Yellow, green, and
blue represent relative expression levels measured in wild type and
two independent Chd7 null ES cell lines, respectively.
Found at: doi:10.1371/journal.pgen.1001023.s005 (0.54 MB EPS)
Table S1 Genes that decrease upon loss of CHD7.
Found at: doi:10.1371/journal.pgen.1001023.s006 (0.09 MB
XLS)
Table S2 Genes that increase upon loss of CHD7.
Found at: doi:10.1371/journal.pgen.1001023.s007 (0.13 MB
XLS)
Table S3 Genes that are non-differentially expressed.
Found at: doi:10.1371/journal.pgen.1001023.s008 (0.11 MB
XLS)
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Found at: doi:10.1371/journal.pgen.1001023.s009 (0.03 MB
XLS)
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